Woo Young Sup, Shim In Hee, Lee Sang-Yeol, Lee Dae-Bo, Kim Moon-Doo, Jung Young-Eun, Lee Jonghun, Won Seunghee, Jon Duk-In, Bahk Won-Myong
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Psychiatry, Cancer Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea.
Clin Psychopharmacol Neurosci. 2017 May 31;15(2):177-180. doi: 10.9758/cpn.2017.15.2.177.
Although aripiprazole has been widely used to treat various psychiatric disorders, little is known about the adequate dosage for Asian patients in clinical practice. Hence, we evaluated the initial and maximum doses of aripiprazole from 2004 to 2014 to estimate the appropriate dosage for Korean psychiatric inpatients in clinical practice.
In this retrospective study, we reviewed the medical records of patients who were hospitalized in five university hospitals in Korea from March 2004 to December 2014. The psychiatric diagnosis according to the text revision of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition during index hospitalization and the initial and maximum doses of aripiprazole were evaluated.
There were 74 patients in Wave 1 (2004-2006), 201 patients in Wave 2 (2007-2010), and 353 patients in Wave 3 (2011-2014). The initial doses of aripiprazole in all diagnostic groups were significantly lower in Wave 3 than in Wave 2. The maximum doses of aripiprazole in each diagnostic group were not significantly different among Waves 1, 2, and 3.
The relatively low initial doses of aripiprazole documented in our study may reflect a strategy by clinicians to minimize the side effects associated with aripiprazole use, such as akathisia.
尽管阿立哌唑已被广泛用于治疗各种精神疾病,但在临床实践中,对于亚洲患者的合适剂量却知之甚少。因此,我们评估了2004年至2014年期间阿立哌唑的初始剂量和最大剂量,以估算韩国精神科住院患者在临床实践中的合适剂量。
在这项回顾性研究中,我们查阅了2004年3月至2014年12月期间在韩国五所大学医院住院患者的病历。评估了索引住院期间根据《精神疾病诊断与统计手册》第4版文本修订版做出的精神科诊断以及阿立哌唑的初始剂量和最大剂量。
第1波(2004 - 2006年)有74例患者,第2波(2007 - 2010年)有201例患者,第3波(2011 - 2014年)有353例患者。第3波中所有诊断组的阿立哌唑初始剂量均显著低于第2波。第1波、第2波和第3波中各诊断组的阿立哌唑最大剂量无显著差异。
我们研究中记录的阿立哌唑相对较低的初始剂量可能反映了临床医生将与使用阿立哌唑相关的副作用(如静坐不能)降至最低的策略。